Innovent climbs as partner Ollin to be acquired by Johnson & Johnson

By Reuters News

** Shares of China's Innovent Biologics 1801.HK climb 3.2% to HK$86.55, on track for the biggest one-day pct gain since November 5

** Stock touches the highest level since November 12

** Innovative medicines developer and producer says its partner Ollin Biosciences Inc has entered into agreement to be be acquired by Johnson & Johnson JNJ.N, together with the next-generation medicines for patients with vision-threatening eye diseases

** Ollin's lead program OLN324 was discovered by Innovent and out-licensed to Ollin

** Johnson & Johnson JNJ.N said on Monday it had agreed to buy Texas-based biotech Ollin Biosciences for up to $3.33 billion, expanding its pipeline of eye disease therapies

** YTD, Innovent shares up 12.1%, Hang Seng Biotech Index .HSBIO up 0.6%

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.